Samenvatting
Samenvatting boek 5 farmacologie geneeskunde
- Vak
- Instelling
Volledige samenvatting farmacologie boek 5. Met glans geslaagd in eerste zit. Alle delen samen beschikbaar in bundel.
[Meer zien]Voorbeeld 7 van de 69 pagina's
Voorbeeld 7 van de 69 pagina's
In winkelwagen
In winkelwagen
Verkoper
Volgen
Gnkkuleuven
Ontvangen beoordelingen
Voorbeeld van de inhoud
DEEL 5Inleiding: autacoïden bij inflammatie en allergie ........................................................................................6
1. Niet-steroïdale anti-inflammatoire geneesmiddelen .............................................................................7
1.1 Chemie van NSAIDs ...........................................................................................................................7
1.2 Werkingsmechanisme van NSAIDs ....................................................................................................7
1.3 Farmacokinetiek van NSAIDs .............................................................................................................8
1.4 Farmacodynamiek van NSAIDs ..........................................................................................................8
1.5 Indicaties ............................................................................................................................................8
1.6 Bijwerkingen ......................................................................................................................................9
Gastro-intestinaal ................................................................................................................................9
Bloedplaatjes .......................................................................................................................................9
Renaal en cardiovasculair ....................................................................................................................9
Overgevoeligheidsreacties ..................................................................................................................9
Hepatotoxiciteit en hematologische toxiciteit....................................................................................9
1.7 Contra-indicaties en risicopopulaties ..............................................................................................10
1.8 Interacties ........................................................................................................................................10
1.9 Kiezen van een NSAID ......................................................................................................................10
1.10 Bespreking van de individuele groepen NSAIDs ...........................................................................10
A. Salicylaten ......................................................................................................................................10
B. Para-aminofenol derivaten ...........................................................................................................12
C. Indool- en arylazijnzuurderivaten .................................................................................................13
D. Arylpropionzuurderivaten .............................................................................................................13
E. Oxicams ..........................................................................................................................................13
F. Pyrazolonderivaten ........................................................................................................................14
G. Selectieve COX2 inhibitoren (coxibs) ............................................................................................14
Besluit ....................................................................................................................................................14
2. Glucocorticoiden....................................................................................................................................15
2.1 Producten: chemie van glucocorticoiden .......................................................................................15
2.2 Werkingsmechanisme .....................................................................................................................15
2.3 Farmacokinetiek ..............................................................................................................................16
2.4 Farmacodynamiek ...........................................................................................................................16
2.5 Indicaties ..........................................................................................................................................17
2.6 Bijwerkingen ....................................................................................................................................17
Metabole effecten .............................................................................................................................17
1
, Feedback effecten .............................................................................................................................18
Effecten op mesemchymale cellen ...................................................................................................18
Anti-inflammatoire en immunosuppressief effect ...........................................................................19
Effecten in het CZS ............................................................................................................................19
Andere bijwerkingen .........................................................................................................................19
2.7 Risicopopulaties ...............................................................................................................................19
3. Tweedelijns anti-reumatische geneesmiddelen ...................................................................................20
3.1 Disease modifying antirheumatic drugs (DMARDs) ........................................................................20
Conventionele synthetische small molecule DMARDs (csDMARDs) ................................................20
Biological DMARDs (bDMARDs) ........................................................................................................21
Targeted synthetic DMARDs (tsDMARDs).........................................................................................22
3.2 Andere immunomodulatoren .........................................................................................................22
Ciclosporine .......................................................................................................................................22
Tacrolimus, sirolimus en derivaten ...................................................................................................23
Azathioprine ......................................................................................................................................23
Mycofenolaatmofetil .........................................................................................................................23
Monoklonale antistoffen ...................................................................................................................23
4. Farmacotherapie van migraine .............................................................................................................24
4.1 Medicijnen om een aanval te couperen .........................................................................................24
Niet-specifieke anti-migraine geneesmiddelen ................................................................................24
Specifieke anti-migraine geneesmiddelen ........................................................................................24
5. Farmacotherapie van jicht .....................................................................................................................26
Inleiding .................................................................................................................................................26
5.1 NSAIDs..............................................................................................................................................26
5.2 Colchicine .........................................................................................................................................26
5.3 Glucocorticoïden .............................................................................................................................27
5.4 Uricostatica: allopurinol en febuxostat ...........................................................................................27
5.5 Uricosurica: probenecid (organisch zuur) en lesinurad ..................................................................28
5.6 Recombinant uraat oxidase.............................................................................................................28
5.7 Canakinumab ...................................................................................................................................28
Verbeter je inzicht .................................................................................................................................28
6. Farmacotherapie van hooikoorts, uticaria en angio-oedeem: antihistaminica ...................................29
Inleiding .................................................................................................................................................29
Farmacologische effecten .................................................................................................................29
6.1 H1-receptorantagonisten .................................................................................................................30
Eigenschappen, chemie en werkingsmechanisme ...........................................................................30
2
, Farmacokinetiek ................................................................................................................................31
Farmacodynamiek .............................................................................................................................31
Indicaties ............................................................................................................................................31
Relatieve contra-indicaties ................................................................................................................32
Bijwerkingen ......................................................................................................................................32
Interacties ..........................................................................................................................................32
Behandeling van seizoensgebonden allergische rhino-conjunctivitis ..............................................32
7. Farmacotherapie van astma ..................................................................................................................33
7.1 Inleiding ...........................................................................................................................................33
7.2 Anti-astmageneesmiddelen ............................................................................................................33
Kortwerkende beta-2 mimetica ........................................................................................................33
Langwerkende beta-2 mimetica .......................................................................................................34
Corticosteroïden ................................................................................................................................34
Theofylline .........................................................................................................................................35
Anticholinergica .................................................................................................................................36
Leukotrieenreceptor-antagonisten ...................................................................................................36
Andere geneesmiddelen ...................................................................................................................37
Aandachtspunten ..............................................................................................................................37
Inhalatiesystemen .............................................................................................................................37
8. Farmacotherapie van anafylactische reacties .......................................................................................38
Verbeter je inzicht .................................................................................................................................39
9. Farmacotherapie van diabetes mellitus ................................................................................................40
9.1 Insuline en analogen........................................................................................................................40
Structuur, vrijstelling, werking en effecten.......................................................................................40
Farmacokinetiek ................................................................................................................................41
Indicaties ............................................................................................................................................41
Bijwerkingen ......................................................................................................................................41
9.2 Orale antidiabetica ..........................................................................................................................42
Biguaniden .........................................................................................................................................42
Sulfonylureumderivaten of sulfamiden ............................................................................................42
Gliniden ..............................................................................................................................................43
Thiazolidinedionen of glitazonen ......................................................................................................43
Alfa-glucosidase inhibitoren ..............................................................................................................44
Gliptinen ............................................................................................................................................44
Gliflozinen (SGLT2 inhibitoren) .........................................................................................................44
9.3 Incretinemimetica ....................................................................................................................45
3
,10. Farmacotherapie en preventie van osteoporose ...............................................................................46
10.1 Inleiding .........................................................................................................................................46
10.2 Calcium ..........................................................................................................................................47
10.3 Vitamine D .....................................................................................................................................47
10.4 Bifosfonaten ..................................................................................................................................48
10.5 Selectieve oestrogeenreceptor-modulatoren (SERMs) ................................................................49
10.6 Teriparatide ...................................................................................................................................49
10.7 Denosumab....................................................................................................................................50
11. Farmacotherapie van kanker...............................................................................................................51
11.2 Algemeen .......................................................................................................................................51
Eigenschappen van maligne cellen ...................................................................................................51
11.3 Principes in de kankerchemotherapie ..........................................................................................51
Terminologie ......................................................................................................................................52
Nevenwerkingen/toxiciteit op kankertherapie .................................................................................52
1.4 Stoffen..............................................................................................................................................52
Cytotoxische toffen ...........................................................................................................................52
Hormonale stoffen ............................................................................................................................53
Immuuntherapie ................................................................................................................................54
Proteïnekinase inhibitoren ................................................................................................................55
12. Supportieve behandeling bij kanker....................................................................................................56
13. Famacologische aspecten in palliatieve en terminale zorg ................................................................57
13.2 Symptoomcontrole in de palliatieve zorg .....................................................................................57
Pijn .....................................................................................................................................................57
Gastro-intestinale problemen ...........................................................................................................58
Respiratoire problemen ....................................................................................................................59
Neurologische problemen .................................................................................................................60
13.3 Medicatietoedieningsroutes .........................................................................................................61
14. Farmacotherapie van het gastrointestinaal stelsel .............................................................................62
14.1 Farmacotherapie van peptische aandoeningen: ulcera en GERD ................................................62
H2-receptorantagonisten ..................................................................................................................62
Protonpompinhibitoren ....................................................................................................................63
Misoprostol ........................................................................................................................................63
Antacida .............................................................................................................................................64
Antibiotica ..........................................................................................................................................64
14.2 (Gastro)-prokinetica ......................................................................................................................64
Dopamine-2-receptorantagonisten ..................................................................................................64
4
, Cisapride ............................................................................................................................................65
14.3 Anti-emetica ..................................................................................................................................65
14.4 Pancreasenzym-substituut ............................................................................................................65
14.5 Laxantia ..........................................................................................................................................66
14.6 Anti-diarrheïca ...............................................................................................................................66
14.7 Farmaca bij inflammatoir darmlijden ......................................................................................66
14.8 Behandeling van infestatie met wormen ......................................................................................67
Addendum 1: geneesmiddelen en QT-verlenging ....................................................................................68
Addendum 2: casusbespreking ............................................................ Fout! Bladwijzer niet gedefinieerd.
5
, INLEIDING: AUTACOÏDEN BIJ INFLAMMATIE EN ALLERGIE
Autacoïden
• = endogene stoffen
• Rol in normale celhomeostase
• Rol bij weefselbeschadiging en ontstekingsreacties
o Oa prostanoïden (behoren tot de eicosanoïden)
• Rol bij allergische reacties
• Lokale hormonen, wnt korte halfwaardetijd
o -> autocriene effecten (effecten op cel waardoor ze worden afgescheiden)
o -> paracriene effecten (effecten op naburige cellen)
• Bevatten: neurotransmitters, peptiden, vetzuurderivaten en anorganische moleculen
6
, 1. NIET-STEROÏDALE ANTI-INFLAMMATOIRE GENEESMIDDELEN
• Meeste NSAIDs remmen COX1 en COX2 -> dus remmen synthese PGs en TXs
• - COX2 is waarschijnlijk de oorzaak van de beoogde analgestische, antipyretische en anti-
inflammatoire effecten
• - COX 1 is waarschijnlijk de oorzaak van de ongewenste effecten
• PG = prostaglandines
• LT = leukotreïnen
• TX = tromboxanen
1.1 CHEMIE VAN NSAIDS
• Heterogenen groep verbindingen (meestal zwakke zuren) met gemeenschappelijk
werkingsmechanisme
• Aspirine = prototype
• Onderscheid volgens chemische structuur
o Salicylaten: acetylsalicylzuur, sulfasalazine
o Para-aminofenol of anniline derivaten: paracetamol, fenacetine
o Indool- en arylazijnzuurderivaten: indometacine, diclofenac, aclefenac, ketorolac
o Arylpropionzuurderivaten: ibuprofen, naproxen
o Oxicams: meloxicam, piroxicam, tenoxicam
o Pyrazolonderivaten: metamizol, fenylbutazon
o COX-2 selectieve NSAIDs of Coxibs: celecoxib, etoricoxib, parecoxib
o Fenamaten of N-fenylanthranylzuurdervitane: mefenaminezuur, meclofenaminezuur
1.2 WERKINGSMECHANISME VAN NSAIDS
• Acetylsalicylzuur is enige NSAID dat covalent (irreversiebel) bindt aan COX1 en COX2
Andere binden reversibel
à inhibitie synthese prostanoïden (PGs en TXs)
à kan onrechtstreeks ook leiden tot verhoogde aanmaak van LT door grotere aanbod van
substraat aan enzyme lipoxygenase
• Goede correlatie tussen in vitro potentie en in vivo anti-inflammatoire activiteit
• Inhibitie niet selectief voor COX 1 of COX 2, maar toch verschillende gevoeligheid -> sommige
preferentieel COX-1 inhibitie, andere preferentieel COX-2 inhibitie
7
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper Gnkkuleuven. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor $10.31. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 79202 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen
Laatst bekeken door jou
